Peer-influenced content. Sources you trust. No registration required. This is HCN.

BloodEnasidenib vs. Conventional Care in Older Patients with Late-stage Mutant-IDH2 Relapsed/Refractory AML: A Randomized Phase 3 Trial

Event-free survival (EFS) was significantly increased with enasidenib compared to conventional care regimens (CCR) in this open-label, randomized, phase 3 trial; overall survival (OS) was complicated by early dropout and usage of later AML medications. The older R/R mutant-IDH2 AML group received notable morphologic and hematologic responses from enasidenib as opposed to CCR.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form